Treatments that target interleukins, such as IL-27, IL-28, IL-29, IL-31, IL-32, and IL-33, have shown promise in reducing fibrosis and inflammation, two important processes linked to the development of heart disorders such as atherosclerosis and heart failure. Here, IL33 is linked to heart disorder.